sickrest.icu

Inflammation is a biological response of the body to protect itself from harmful internal and external stimuli and start healing. It is a part of the body’s immune system and protects us from infections, wounds and tissue damage. Inflammation can be acute where it can start quickly and become severe in a short span of time. For example, acute inflammation can cause diseases and conditions like sinusitis, a sore throat from a cold, acute bronchitis, etc. Inflammation can be chronic in response to unwanted toxins in the body like cigarette smoke or excess body fat. This may extend from months to years that may lead to conditions like rheumatoid arthritis, asthma and non-infectious conditions like tuberculosis, peptic ulcer, hepatitis, etc.

What causes chronic inflammation?

Stress: Stress causes activity in the brain that can lead to physical pain which may lead to an inflammatory response in the body. Hence, people suffering from stress may experience inflammation.

Poor diet: Some foods like simple sugars, high fructose corn syrup, refined flours, trans-fat-rich foods, processed meat, fried foods, etc. can trigger the inflammatory response in the body. So the consumption of these food items should be restricted.

Unhealthy lifestyle: Consumption of alcohol, smoking, leading a sedentary life and being overweight creates a stress in the body that triggers an inflammatory response.

Pollution: Pollution causes damage to the cells which may cause inflammation.How can you be safe from chronic inflammation?

Regular physical activity: The regular physical activity of 30 – 50 minutes will help you reduce weight and will also help you to mobilize the joints. This will reduce the chances of developing chronic inflammation.

Having a well-balanced and nutritious diet: Do include all the food groups in your diet. Have foods rich in omega 3 fatty acids, fibre, magnesium, carotenoids, antioxidants and lycopene as these nutrients are anti-inflammatory.

Some anti-inflammatory foods are:

Olive oil
Tomatoes
Nuts, such as walnuts and almonds
Leafy greens, including spinach and kale
Fatty fish, such as salmon and mackerel
Fruits, especially blueberries, oranges and cherries
Spices like ginger, turmeric, oregano and cloves
Relieve yourself of stress: Sleeping for a minimum of 6-8 hours a day, trying and using stress relaxation techniques, talking about how you feel, etc will help you in maintaining and lowering your stress. This reduces the chances of inflammation.

Understanding the link between chronic inflammation, diet and exercise will help in ageing healthily and keep chronic diseases at bay. Eating an overall healthy diet rather than singling out foods and incorporating them into your diet is the best way to fight inflammation. Unprocessed, plant-based foods with a variety of colours will ensure your body is protected from inflammation.

If you are looking to improve the overall quality of life with different foods or need a healthy weight loss programs, dietitians in Mumbai and nutritionist in Mumbai can help you plan these meals at our weight loss clinic in Mumbai.

Biosimilar is a biological product that resembles a reference product and is not difference from the already approved reference product. These are relatively cheaper than branded or approved products. Several biologics for oncology have already lost their patents, and some are in its period of expiry. As more products are expected to lose patents, biosimilar is expected to gain popularity. Leading generic players such as Mylan N.V., Teva Pharmaceutical Industries Ltd, Allergan Plc, Sandoz (a Novartis International AG’s division) are expected to capitalize on these patent expiries and may establish themselves as dominating players in oncology biosimilars market.

Click To Continue Reading on Oncology Biosimilars Market

There was about a decade gap in approval of first biosimilars in two key markets, Europe and the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product was approved in 2015. But since approving the first biosimilar, the FDA has approved five products in 2017. Out of these five biosimilars, two were approved for oncology. First, oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the products have been approved, and Mvasi received approval from European Commission in January 2018.

Moreover, there are number of biosimilar application pending in the U.S. and Europe. For Herceptin (trastuzumab) alone, there are around four application pending in the FDA. These four application are from Amgen and Allergan, Celltrion and Teva, Pfizer, and Samsung Bioepis. Recent approval of products, and potential approval in next few years is expected to boost the market growth over the forecast period.

On the basis of region, oncology biosimilars market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the dominant market over the forecast period. U.S. FDA approved first biosimilar in 2015, almost a decade later than first biosimilar approval in Europe. However, since 2015, the number of approved products has increased rapidly. This is expected to be factor for growth of the market in North America. Moreover, currently there are number of products in pipeline, which may receive approval from the FDA over the forecast period. For instance, Pfizer Inc. — a U.S.-based company — has three biosimilar products (i.e. PF-05280014, PF-05280586 and PF-06439535) for oncology in Phase 3.